Last reviewed · How we verify
LY06006
LY06006 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in disease pathogenesis.
LY06006, a monoclonal antibody developed by Luye Pharma Group Ltd., is in Phase 3 trials for osteoporosis. It aims to match the efficacy and safety of Prolia, with completed Phase 1 studies showing promising pharmacokinetic similarity.
At a glance
| Generic name | LY06006 |
|---|---|
| Also known as | subcutaneous injection of 60 mg, recombinant human monoclonal anti-RANKL antibody injection |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
LY06006 is an investigational compound in phase 3 development by Luye Pharma Group. Limited public information is available regarding its precise molecular mechanism and target. The drug is being evaluated for therapeutic potential, but detailed mechanistic data from published sources is not readily accessible.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY06006 CI brief — competitive landscape report
- LY06006 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI